A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)
Titel:
A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)
Auteur:
Powles, T. Brown, J. Larkin, J. Jones, R. Ralph, C. Hawkins, R. Chowdhury, S. Boleti, E. Bhal, A. Fife, K. Webb, A. Crabb, S. Geldart, T. Hill, R. Dunlop, J. Hall, P.E. McLaren, D. Ackerman, C. Beltran, L. Nathan, P.